Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | CES2 | O00748 | 2/20 | 0.59 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68152 | 1.00 | KMT2A (0.64) | KMT2ACES2CES1MEN1PTGS1 | |
| SCHEMBL318731 | 1.00 | KMT2A (0.64) | KMT2ACES2CES1MEN1PTGS1 | |
| SCHEMBL1428029 | 0.89 | KMT2A (0.52) | KMT2ACES2CES1PTGS2ALDH1A1 | |
| SCHEMBL1565875 | 0.86 | MAPK1 (0.51) | KMT2ACES2CES1PTGS1ALDH1A1 | |
| SCHEMBL13522785 | 0.84 | KMT2A (0.51) | KMT2ACES2CES1MEN1PTGS1 | |
| SCHEMBL9000507 | 0.82 | PTGS1 (0.59) | KMT2AMEN1PTGS1PTGS2 | |
| SCHEMBL8881032 | 0.82 | ESR1 (0.54) | KMT2APTGS1ALDH1A1LMNASLC6A3 | |
| SCHEMBL4776154 | 0.82 | L3MBTL1 (0.45) | KMT2AALDH1A1LMNA | |
| SCHEMBL1564938 | 0.82 | CYP1A2 (0.50) | KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL4013605 | 0.82 | L3MBTL1 (0.46) | KMT2AMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708354-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | disclosed |
| CN-110325528-B | 2-benzopyrazinyl-N-heteroaryl-2-phenyl-acetamide compounds | 豪夫迈·罗氏有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3558967-B1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-03-02 | — | — | EP | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| CN-103052636-B | D 2antagonist and synthetic method thereof and using method | Altos Therapeutics, LLC (US) | 2016-03-09 | — | — | CN | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| EP-2582701-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| CN-103052636-A | D2 antagonists, methods of synthesis and methods of use | ALTOS THERAPEUTICS LLC | 2013-04-17 | — | — | CN | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| WO-2011160084-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | KMT2A 2446/4885CES2 848/4885CES1 1984/4885 |
| US-11708354-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | EGFR, ERBB2, ERBB3 | KMT2A 972/4885CES2 1607/4885CES1 3295/4885 |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | KMT2A 2446/4885CES2 848/4885CES1 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.